Abstract: The present disclosure relates to molecules with a solubility tag, wherein the solubility tag comprises a chito-oligosaccharide, and to methods for increasing the solubility of a molecule. Moreover, the present disclosure relates to antibody-drug conjugates with solubility tag, methods and compounds for preparing such antibody-drug conjugates, methods for increasing the solubility of antibody-drug conjugates, antibody-drug conjugates prepared by such methods, as well as the use of such antibody-drug conjugates in medical treatment.

Abstract: The invention provides a method for eluting a monoclonal antibody from a Protein A affinity chromatography column to which the monoclonal antibody is bound comprising a) contacting the affinity chromatography column with an elution buffer comprising a poly (ethylene glycol) polymer; b) collecting one or more fractions containing the monoclonal antibody obtained from step (a) c) combining the fractions obtained from step (b) to form an elution product pool.

Abstract: A method for purifying a target protein from a cell culture sample containing the target protein, viral compounds and other impurities, by affinity chromatography virus inactivation and optionally other purifications the affinity chromatography involving a) loading an affinity chromatography column with the cell culture sample thereby binding the target protein to the affinity chromatography column; b) eluting the target protein from the affinity chromatography column by contacting the affinity chromatography column with an elution buffer having a pH<6 and comprising an excipient, wherein the excipient is disaccharides, polyols or poly (ethylene glycol) polymers; c) collecting one or more fractions containing the target protein obtained from (b); d) potentially combining the fractions obtained from (c) to form an elution product pool, and wherein the virus inactivation involves e) incubating the elution product pool at a pH from 2.5 to 4.5.

Abstract: The present invention relates to a method for stabilizing protein or peptide comprising formulations, which includes the step of adding selected meglumine salts to protein solutions, especially to solutions of pharmaceutical active proteins. But the present invention also relates to the stabilized composition comprising proteins or peptides and selected meglumine salts. Another objective of the present invention is to provide pharmaceutical compositions comprising antibody molecules stabilized by selected meglumine salts and methods for producing corresponding stabilized pharmaceutical compositions, and kit comprising these compositions.